// App-Quantinova.ai

M2170 2016 AHA : A Paradoxical Relationship of Plasma Adiponectin to Cardiovascular Risk in Patients With Diabetes and Recent Acute Coronary Syndrome - the Alecardio Trial

Researchers

Presenter

  • Anna Nozza

Principal Investigators

  • Barbara E Stahli

  • Sahlgrenska Acad

  • Arlette Weichert

  • A. Michael Lincoff

  • Jean-Claude Tardif

  • Diederick E Grobbee

  • Gregory G Schwartz

  • John B Buse

  • Klas Malmberg

  • Karolinska Instt

  • Bruce Neal

  • Stephan J Nicholls

  • Lars Ryden

  • Anders Svensson

  • Hans Wedel

Medical Centers

  • Univ de Montreal and Montreal Heart Inst, Montreal, QC, Canada

  • University of Adelaide, Adelaide, Australia

  • Karolinska Institutet, Stockholm, Sweden

  • VA Medical Ctr and Univ of Colorado Sch of Med, Denver, CO

  • Stockholm and Antaros Medical, Gothenburg, Sweden

  • Cleveland Clinic Coordinating Ctr for Clinical Res, Cleveland, OH

  • Univeristy of Gothenburg, Gothenburg, Sweden.

  • The George Institute for Global Health, The University of Sydney, Sydney, Australia

  • Univ of N Carolina Schl of Med, Chapel Hill, NC

  • Julius Clinical and Julius Ctr for Health Sciences and Primary Care, Univ Medical Ctr Utrecht, Utrecht, Netherlands

  • Montreal Heart Inst, Montreal Health Innovations Coordinating Ctr MHICC, Montreal, QC, Canada

Locations

  • Canada

  • Netherlands

  • Australia

  • United States

  • Sweden

Companies

  • Feng Chi Biotech Cor

Study Components

Therapeutic Area

  • Central Nervous System (CNS)

Disease

  • Acute Coronary Syndromes

  • Myocardial infarction

  • Type 2 diabetes mellitus

  • Diabetes

  • Stroke

Biomarkers

  • Adiponectin

  • Peroxisome proliferator activated receptor

Drug/Treatment

  • Aleglitazar

Outcome

  • N/A

Study Design

  • observational

  • randomized

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved